NCT05217303View on ClinicalTrials.gov

HL-085 in NRAS-mutated Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

February 19, 2023

Study Completion Date

February 20, 2023

Conditions
Melanoma
Interventions
DRUG

HL-085

HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

Unknown

Beijing Oncology Hospital, Beijing

All Listed Sponsors
lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT05217303 - HL-085 in NRAS-mutated Advanced Melanoma | Biotech Hunter | Biotech Hunter